Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zai Lab Raises $750 Million in Public Offering

publication date: Apr 21, 2021

Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. Led by Samantha Du, PhD, an early China drug developer, Zai began as a China-based in-licensing company that has since expanded into novel drug development. It currently has a portfolio of 21 products. Zai has a market cap of $14 billion and over $1 billion in cash, not including this latest raise. The company said it will direct 30% of the proceeds to additional business development and licensings. More details....

Stock Symbol: (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021